NCT02461589已完成2 期
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 706
- 试验地点
- 1
- 主要终点
- Change in HbA1c (Glycosylated Haemoglobin)
研究概览
简要总结
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, age at least 18 years at the time of signing informed consent.
- •Subjects should be on stable diabetes treatment consisting of diet and exercise with or without metformin (at least 1500 mg daily or maximum tolerated dose documented in the patient medical record) for at least 90 days prior to screening
- •HbA1c (glycosylated haemoglobin): 53-86 mmol/mol (7.0-10.0%) (both inclusive)
- •BMI: 25.0 - 40.0 kg/m^2 (both inclusive)
排除标准
- •Simultaneous participation in any other clinical trial of an investigational medicinal product
- •Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods throughout the trial including the 7 weeks follow-up period (adequate contraceptive measures as required by local regulation or practice). Germany: Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine device), or sexual abstinence or vasectomised partner. United Kingdom: Adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), female sterilisation, male sterilisation (where partner is sole partner of subject), or true abstinence (when in line with preferred and usual lifestyle)
- •Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening (an exception is short-term insulin treatment for acute illnesses for a total of below or equal to 14 days)
- •Anticipated initiation or change in concomitant medications (for more than 14 consecutive days or on an frequent basis) known to affect weight or glucose metabolism (e.g. orlistat, thyroid hormones, corticosteroids)
- •History of pancreatitis (acute or chronic)
- •Screening calcitonin above or equal to 50 ng/L
- •Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroid Carcinoma (MTC)
- •Severe to moderate renal impairment defined as GFR, estimated below 60 ml/min/1.73 m^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology)
- •Within the past 180 days before screening any of the following: Myocardial infarction, stroke or hospitalisation for unstable angina and/or transient ischemic attack
- •Currently planned coronary, carotid or peripheral artery revascularisation
- •Patients presently classified as being in New York Heart Association (NYHA) Class III or IV
研究组 & 干预措施
Liraglutide 0.3/0.6/1.2 mg/day
Active Comparator
干预措施: liraglutide (Drug)
Placebo 50/100/200 µL
Placebo Comparator
干预措施: placebo (Drug)
Semaglutide 0.05 mg/day
Experimental
干预措施: semaglutide (Drug)
Liraglutide 0.3 mg/day
Active Comparator
干预措施: liraglutide (Drug)
Placebo 50 µL
Placebo Comparator
干预措施: placebo (Drug)
Semaglutide 0.05/0.1 mg/day
Experimental
干预措施: semaglutide (Drug)
Liraglutide 0.3/0.6 mg/day
Active Comparator
干预措施: liraglutide (Drug)
Placebo 50/100 µL
Placebo Comparator
干预措施: placebo (Drug)
Semaglutide 0.05/0.1/0.2 mg/day
Experimental
干预措施: semaglutide (Drug)
Semaglutide 0.05/0.1/0.2/0.3 mg/day
Experimental
干预措施: semaglutide (Drug)
Liraglutide 0.3/0.6/1.2/1.8 mg/day
Active Comparator
干预措施: liraglutide (Drug)
Placebo 50/100/200/300 µL
Placebo Comparator
干预措施: placebo (Drug)
Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day
Experimental
干预措施: semaglutide (Drug)
结局指标
主要结局
Change in HbA1c (Glycosylated Haemoglobin)
时间窗: Week 0, week 26
Estimated mean change from baseline in HbA1c at week 26. The data were analysed for the "on-treatment until rescue medication" observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.
次要结局
- Body Weight Change(Week 0, Week 26)
- Change in Systolic and Diastolic Blood Pressure(Week 0, Week 26)
- Change in Fasting Plasma Glucose (FPG)(Week 0, Week 26)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.Hepatobiliary DisordersNon-alcoholic SteatohepatitisNCT02970942Novo Nordisk A/S320
已完成
3 期
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT02054897Novo Nordisk A/S388
已完成
3 期
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.DiabetesDiabetes Mellitus, Type 2NCT02849080Novo Nordisk A/S504
已完成
3 期
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT02607865Novo Nordisk A/S1,864
已完成
3 期
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With InsulinDiabetesDiabetes Mellitus, Type 2NCT03021187Novo Nordisk A/S731